Balchem (BCPC) Q3 2025 earnings summary

Executive summary

• Achieved record Q3 2025 consolidated sales of $267.6 million, up 11.5% year-over-year, with all business segments contributing to strong top and bottom line results.

• Net earnings rose 19.1% to $40.3 million, and adjusted EBITDA reached $71.4 million, up 11.0% year-over-year.

• Robust free cash flow and disciplined capital allocation supported share repurchases, dividends, and ongoing investments.

• Strong performance driven by market penetration of specialty nutrients, delivery systems, and alignment with better-for-you food trends.

• Diversified supply chain and manufacturing footprint limited the net impact of tariff and trade environment.

Financial highlights

• Q3 2025 consolidated revenue reached $267.6 million, up 11.5% year-over-year; gross margin was $95.5 million (35.7% of sales), up 11.8%.

• GAAP earnings from operations were $54.6 million, up 13.7%; net income was $40.3 million, up 19.1%.

• Diluted GAAP EPS was $1.24, up from $1.03; adjusted EPS was $1.35, up from $1.13 year-over-year.

• Adjusted EBITDA was $71.4 million, up 11.0% year-over-year, with a margin of 26.7%.

• Free cash flow for Q3 2025 was $50.7 million; cash on balance sheet was $65.1 million at quarter end.

Outlook and guidance

• Positive outlook for the remainder of 2025, with continued strong cash flow generation and ability to offset tariff impacts.

• Focus on strengthening positions in attractive, growing markets, driving organic growth, and executing strategic M&A.

• Continued investment in innovation, geographic expansion, and portfolio broadening to sustain above-market growth.

• Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products segments expected to continue delivering growth.

• Effective tax rate for Q3 2025 was 22.6%, with 2025 expected to be around 22.5%.